EXHIBIT 99-1
3250 Mary Street, Suite 402
Miami, Florida 33133
Main number: 305-448-4700
Fax: 305-448-4757
www.omnicomm.com
OmniComm Systems, Inc.'s Appoints
Dr. David Ginsberg Chief Executive Officer
MIAMI, FL - July 31, 2000--OmniComm Systems, Inc. (OTC-BB: OMCM), a developer of
e-health information systems and provider of online clinical solutions for the
pharmaceutical and healthcare industries, announced today that Dr. David
Ginsberg will join the company as President and Chief Executive Officer.
Dr. Ginsberg has functioned as a principal investigator for several hundred
industry sponsored clinical trials worldwide over 17 years and is the author of
the definitive practical guide to clinical research, The Investigator's Guide to
Clinical Research, which is also published in Japanese. Dr. Ginsberg also has
worked as an executive director for Covance Inc. (NYSE: CVD), one of the world's
largest and most comprehensive drug development services companies, where he
created initiatives, interacted with investigators, and integrated health
systems and academic medical centers on a global basis. He was also the Vice
President of Field Operations for Wyeth-Ayerst Research, the pharmaceutical
division for American Home Products (NYSE: AHP) where he managed Operations for
Research and Development worldwide. Dr. Ginsberg has worked as an investigator,
advisor, visiting expert and consultant for over 40 of the major pharmaceutical
companies worldwide including Eli Lilly (NYSE: LLY), Glaxo Pharmaceuticals
(NYSE: GLX), and Pfizer, Inc. (NYSE: PFE).
"Dr. Ginsberg's strategic vision coupled with his more than 17 years of
experience in leading clinical trials globally will prove invaluable to OmniComm
as we continue to position the Company as a leader in e-Health," said Cornelis
Wit, interim CEO of OmniComm. Mr. Wit, a member of the Board of Directors, will
continue on in an advisory role during the initial transition period.
"OmniComm's business and technical models perfectly position our company to take
advantage of the competitive pressures that are forcing a complete redesign of
the existing clinical trials process in the pharmaceutical and healthcare
industries," said Dr. Ginsberg. "I look forward to leading this global team that
is creating the premiere `netsourcing partner' for our industry to expand
patient access and enhance data quality while further reducing costs and time to
market."
About OmniComm
OmniComm (http://www.omnicomm.com) has developed a unique business model
designed to integrate health information systems and coordinate the processes
necessary to utilize health information. The development of the internet
application, TrialMaster(TM), together with the web portal, WebIPA(TM), enables
OmniComm to straddle the divide between doctors and their patients, possessing
invaluable data for the healthcare industry; and the pharmaceutical/medical
device industries which desperately needs the doctors, patients and data
required for the clinical trial industry.
TrialMaster provides the pharmaceutical/medical device companies with an
Internet-based solution which greatly increases the efficiency, security and
integrity of the clinical trial process while drastically reducing the time and
expense of conducting a trial. OmniComm, with its systems integration background
<PAGE>
and expertise, provides not only the application, but also the physical
infrastructure and networking design capabilities so fundamentally important to
maintaining an effective Internet application. WebIPA provides the interface
between patients, doctors and the clinical trial industry. It enables patients
and physicians to interact and to investigate the various opportunities to
participate in clinical trials. WebIPA also allows the clinical research
industry the ability to interface with patients and doctors, expanding the
critical population of trial participants and providing an invaluable research
database.
In conjunction with WebIPA.com (http://www.webipa.com), OmniMed Services, Inc.,
a wholly owned subsidiary of OmniComm Systems, Inc. is assembling an extensive
network of physician practice groups and related patients. OmniMed provides the
clinical trial industry a vast pool of potential physicians and patients from an
extremely diverse spectrum of medical specialties to participate in a wide
variety of clinical trials. In addition, OmniMed provides the clinical trial
industry with an extensive database of valuable information from previous
clinical trials.
Safe Harbor Statement
Statements about OmniComm's future expectations, including without limitation,
future revenues and earnings, plans and objectives for the future operations,
future agreements, future economic performance, operations and all other
statements in this press release other than historical facts are
"forward-looking statements" within the meeting of Section 27A of the Securities
Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that
term is defined in the Private Securities Litigation Reform Act of 1995.
OmniComm intends that such forward-looking statements be subject to the safe
harbors created thereby. Since these statements involve risks and uncertainties,
including but not limited to economic, competitive, governmental, contractual
and technological factors affecting OmniComm's operations, markets and
profitability, actual results could differ materially and adversely from the
expected results.
Contacts:
Ron T. Linares
OmniComm Systems, Inc.
Phone: 305-448-4700
e-mail: [email protected]
